Trials / Sponsors / Sumithira Vasu
Sumithira Vasu
Academic / Other · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia | Phase 1 | 2022-06-30 |
| Recruiting | Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor | EARLY_Phase 1 | 2020-11-07 |
| Completed | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia | Phase 1 | 2020-06-11 |
| Terminated | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2020-01-10 |
| Completed | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hema Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | 2015-07-27 |
| Completed | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | 2015-04-21 |